To the Editor. —
Colice is to be commended for his meticulous effort, through the use of decision analysis,1 to resolve the controversy regarding isoniazid chemoprophylaxis for young purified protein derivative (PPD) reactors of unknown date of conversion, with a normal chest roentgenogram, and with no additional risk factors for developing tuberculosis. As he notes, three previous decisionanalysis studies have reached conflicting conclusions. With the addition of the current study, the "score" now stands as two1,2 favoring the American Thoracic Society/Centers for Disease Control recommendation, and two3,4 failing to support it.In all of these studies,1-4 the decision trees are similar in design in that the "no isoniazid" limb is followed by a "tuberculosis—no tuberculosis" chance node. What is missing in terms of clinical relevance is a "risk factorno risk factor" branch point prior to the possible development of tuberculosis. Those physicians who advocate not giving
Berger R, Rehm S. Decision Analysis for Isoniazid Chemoprophylaxis. Arch Intern Med. 1991;151(12):2476–2477. doi:10.1001/archinte.1991.00400120108026
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.